<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01272804</url>
  </required_header>
  <id_info>
    <org_study_id>B1621003</org_study_id>
    <nct_id>NCT01272804</nct_id>
  </id_info>
  <brief_title>Multiple Dose Study Of PF-04937319 In Patients With Type 2 Diabetes</brief_title>
  <official_title>A Phase 1 Placebo-controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Oral Doses Of Pf-04937319 In Adult Patients With Type 2 Diabetes Mellitus (t2dm)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK),
      and pharmacodynamics (PD) of PF-04937319 following multiple (14 days) escalating oral doses
      in patients with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline (Day 1) up to 14 days after last dose of study treatment (up to 28 days)</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 14 days after last dose that were absent before treatment or that worsened relative to pre-treatment state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) On Day 1</measure>
    <time_frame>0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours (hrs) post morning dose on Day 1 (fasted condition)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) On Day 6</measure>
    <time_frame>0 (pre-dose), 0.5, 1.5, 3, 5, 8 hours post-dose on Day 6 (fed condition)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1</measure>
    <time_frame>0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 1 (fasted condition)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 6</measure>
    <time_frame>0 (pre-dose), 0.5, 1.5, 3, 5, 8 hours post-dose on Day 6 (fed condition)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) on Day 1</measure>
    <time_frame>0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 1 (fasted condition)</time_frame>
    <description>AUCtau is the area under the plasma concentration versus time curve from time zero (pre-dose) to the end of the dosing interval (tau), here dosing interval is 24 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration at Steady State (Cmax, ss) On Day 14</measure>
    <time_frame>0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 14 (fasted condition)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration at Steady State (Tmax, ss) on Day 14</measure>
    <time_frame>0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 14 (fasted condition)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to End of Dosing Interval at Steady State (AUCtau, ss) on Day 14</measure>
    <time_frame>0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 14 (fasted condition)</time_frame>
    <description>AUCtau, ss = Area under the plasma concentration versus time curve from time zero (pre-dose) to the end of the dosing interval (tau) at steady state, here dosing interval is 24 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Decay Half-Life (t1/2) on Day 14</measure>
    <time_frame>0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24, 36, 48 hours post morning dose on Day 14 (fasted condition)</time_frame>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum Observed Plasma Trough Concentration at Steady State (Cmin, ss) on Day 14</measure>
    <time_frame>0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16 hours post morning dose on Day 14 (fasted condition)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Unchanged Drug Excreted in the Urine Over Dosing Interval (Ae[%]) on Day 14</measure>
    <time_frame>0 hour (pre-dose) through 24 hours post-dose on Day 14</time_frame>
    <description>Percentage of drug excreted unchanged in urine calculated as overall amount of unchanged drug excreted in the urine over the dosing interval (24 hours) divided by total daily dose multiplied by 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Oral Clearance (CL/F) on Day 14</measure>
    <time_frame>0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 14 (fasted condition)</time_frame>
    <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) on Day 14</measure>
    <time_frame>0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 14 (fasted condition)</time_frame>
    <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Accumulation Ratio for AUCtau (Rac)</measure>
    <time_frame>0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 1 and Day 14 (fasted condition)</time_frame>
    <description>Accumulation ratio for AUCtau (Rac) was calculated as area under the curve from time zero to end of dosing interval (AUCtau) on Day 14 divided by area under the curve from time zero to end of dosing interval (AUCtau) on Day 1. Dosing interval = 24 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Accumulation Ratio for Cmax (Rac, Cmax)</measure>
    <time_frame>0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 1 and Day 14 (fasted condition)</time_frame>
    <description>Accumulation ratio for Cmax (Rac, Cmax) was calculated as maximum observed plasma concentration (Cmax) on Day 14 divided by maximum observed plasma concentration (Cmax) on Day 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change From Baseline in Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1</measure>
    <time_frame>-46, -45.75, -45.5, -45, -44.5, -44, -43, -42 hrs pre-dose on Day -1; 2, 2.25, 2.5, 3, 3.5, 4, 5, 6 hrs post-dose on Day 1 (fasted condition)</time_frame>
    <description>Percent change from baseline in area under the plasma glucose concentration-time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC. Baseline value was the AUC (2-6) calculated on Day -1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change From Baseline in Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 14</measure>
    <time_frame>-46, -45.75, -45.5, -45, -44.5, -44, -43, -42 hrs pre-dose on Day -1; 2, 2.25, 2.5, 3, 3.5, 4, 5, 6 hrs post-dose on Day 14 (fasted condition)</time_frame>
    <description>Percent change from baseline in area under the plasma glucose concentration-time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC. Baseline value was the AUC (2-6) calculated on Day -1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Insulin Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14</measure>
    <time_frame>-46, -45.75, -45.5, -45, -44.5, -44, -43, -42 hrs pre-dose on Day -1; 2, 2.25, 2.5, 3, 3.5, 4, 5, 6 hrs post-dose on Day 1 and 14 (fasted condition)</time_frame>
    <description>Percent change from baseline in area under the plasma insulin concentration-time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC. Baseline value was the AUC (2-6) calculated on Day -1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in C-peptide Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14</measure>
    <time_frame>-46, -45.75, -45.5, -45, -44.5, -44, -43, -42 hrs pre-dose on Day -1; 2, 2.25, 2.5, 3, 3.5, 4, 5, 6 hrs post-dose on Day 1 and 14 (fasted condition)</time_frame>
    <description>Percent change from baseline in area under the plasma C-peptide concentration-time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC. Baseline value was the AUC (2-6) calculated on Day -1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Plasma Glucose at Day 1, 6, 14</measure>
    <time_frame>-46, -44, -42, -40, -38, -36, -30, -27 hrs pre-dose on Day -1; 2, 6, 8, 10, 12,18,21 hrs post-dose on Day 1, 6 and 14; additional 0 hr (pre-dose) on Day 6 and 4 hr post-dose on Day 1 and 14</time_frame>
    <description>Glucometer testing performed by finger-stick at 8 time points per day to measure glucose levels. Average plasma glucose was calculated as area under the plasma glucose concentration-time curve from 0 to 24 hours (AUC [0-24]) divided by 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15</measure>
    <time_frame>Baseline (Pre-dose on Day 1), Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up</measure>
    <time_frame>Baseline (Day -2), Day 3, 6, 10, 14, 16 and Follow-up (7 to 14 days after last dose of study medication)</time_frame>
    <description>Blood sample for lipid biomarker was taken following 12-hours fasting. Baseline value was collected on Day -2 for lipids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up</measure>
    <time_frame>Baseline (Day -2), Day 3, 6, 10, 14, 16 and Follow-up (7 to 14 days after last dose of study medication)</time_frame>
    <description>Blood sample for lipid biomarker was taken following 12-hours fasting. Baseline value was collected on Day -2 for lipids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up</measure>
    <time_frame>Baseline (Day -2), Day 3, 6, 10, 14, 16 and Follow-up (7 to 14 days after last dose of study medication)</time_frame>
    <description>Blood sample for lipid biomarker was taken following 12-hours fasting. Baseline value was collected on Day -2 for lipids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up</measure>
    <time_frame>Baseline (Day -2), Day 3, 6, 10, 14, 16 and Follow-up (7 to 14 days after last dose of study medication)</time_frame>
    <description>Blood sample for lipid biomarker was taken following 12-hours fasting. Baseline value was collected on Day -2 for lipids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lactate Level at Day 6 and 14</measure>
    <time_frame>Baseline (Day 1), Day 6 and 14</time_frame>
    <description>Baseline value was collected at 0 hour on Day 1 for lactate.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>NIDDM</condition>
  <arm_group>
    <arm_group_label>PF-04937319</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04937319</intervention_name>
    <description>Subjects will be dosed with PF-04937319 for 14 days. The doses planned are 10, 30, 100 and 300 mg QD. All doses will be administered as tablets (10 and 100 mg strengths). In each Cohort, 9 patients will receive PF 04937319 and 3 will receive placebo. An additional cohort of 12 patients (9 active, 3 placebo) may be performed to explore a QD or BID dose. The dose for this additional cohort could be a dose already studied or a new dose that is within the exposure stopping criteria.</description>
    <arm_group_label>PF-04937319</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match PF-04937319 will be provided. Subjects will be dosed for 14 days. In each cohort 9 subjects will receive PF-04937319 and 3 will receive placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with type 2 diabetes mellitus who are taking metformin only.

          -  Treatment should be stable, where this is defined as no change in the treatment,
             including dose, over the past 2 months. Regimens may include once daily and twice
             daily dosing only.

          -  Male and/or female patients (females will be women of non childbearing potential)

          -  Body Mass Index (BMI) of 18.5 to 45.0 kg/m2; and a total body weight &gt;50 kg (110 lbs).

          -  HbA1c between 7.0% and 10.0%.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing). Patients who have chronic conditions other than
             T2DM (for example, hypercholesterolemia or hypertension) but are controlled by either
             diet or stable (for the last 2 months) doses of medications may be included as well
             (for example, a subject with hypercholesterolemia on appropriate treatment is
             eligible).

          -  Evidence or history of diabetic complications with significant end organ damage, eg,
             proliferative retinopathy and/or macular edema, creatinine clearance less than 60
             mL/min

          -  Any condition possibly affecting drug absorption (eg, gastrectomy)

          -  History of stroke or transient ischemic attack or myocardial infarction within the
             past 6 months

          -  History of coronary artery bypass graft or stent implantation.

          -  Clinically significant peripheral vascular disease (eg, manifested by claudication).

          -  Any history or clinical evidence of congestive heart failure, NYHA Classes II to IV.

          -  One or more self reported significant/severe/requiring treatment episodes of
             hypoglycemia within the last 3 months, or two or more self reported
             significant/severe/requiring treatment episodes of hypoglycaemia within the last 6
             months.

          -  Current history of angina/unstable angina.

          -  Milk or soy allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Elite Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MRA Clinical Research</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medpace Clinical Pharmacology Unit</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1621003&amp;StudyName=Multiple%20Dose%20Study%20Of%20PF-04937319%20In%20Patients%20With%20Type%202%20Diabetes</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2011</study_first_submitted>
  <study_first_submitted_qc>January 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2011</study_first_posted>
  <results_first_submitted>December 6, 2016</results_first_submitted>
  <results_first_submitted_qc>December 6, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 1, 2017</results_first_posted>
  <last_update_submitted>December 6, 2016</last_update_submitted>
  <last_update_submitted_qc>December 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics PK Pharmacodynamics PD T2DM Phase 1 Type 2 diabetes mellitus safety and tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PF-04937319 10 mg</title>
          <description>Participants received PF-04937319 10 milligram (mg) tablet orally once daily for 14 days.</description>
        </group>
        <group group_id="P2">
          <title>PF-04937319 30 mg</title>
          <description>Participants received PF-04937319 30 mg (3 tablets of 10 mg) orally once daily for 14 days.</description>
        </group>
        <group group_id="P3">
          <title>PF-04937319 50 mg</title>
          <description>Participants received PF-04937319 50 mg (5 tablets of 10 mg) orally once daily for 14 days.</description>
        </group>
        <group group_id="P4">
          <title>PF-04937319 100 mg</title>
          <description>Participants received PF-04937319 100 mg tablet orally once daily for 14 days.</description>
        </group>
        <group group_id="P5">
          <title>PF-04937319 300 mg</title>
          <description>Participants received PF-04937319 300 mg (3 tablets of 100 mg) orally once daily for 14 days.</description>
        </group>
        <group group_id="P6">
          <title>Placebo</title>
          <description>Participants received placebo matched to PF-04937319 tablet orally once daily for 14 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis set included all participants who received at least 1 dose of study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>PF-04937319 10 mg</title>
          <description>Participants received PF-04937319 10 milligram (mg) tablet orally once daily for 14 days.</description>
        </group>
        <group group_id="B2">
          <title>PF-04937319 30 mg</title>
          <description>Participants received PF-04937319 30 mg (3 tablets of 10 mg) orally once daily for 14 days.</description>
        </group>
        <group group_id="B3">
          <title>PF-04937319 50 mg</title>
          <description>Participants received PF-04937319 50 mg (5 tablets of 10 mg) orally once daily for 14 days.</description>
        </group>
        <group group_id="B4">
          <title>PF-04937319 100 mg</title>
          <description>Participants received PF-04937319 100 mg tablet orally once daily for 14 days.</description>
        </group>
        <group group_id="B5">
          <title>PF-04937319 300 mg</title>
          <description>Participants received PF-04937319 300 mg (3 tablets of 100 mg) orally once daily for 14 days.</description>
        </group>
        <group group_id="B6">
          <title>Placebo</title>
          <description>Participants received placebo matched to PF-04937319 tablet orally once daily for 14 days.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="9"/>
            <count group_id="B6" value="16"/>
            <count group_id="B7" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.6" spread="9.2"/>
                    <measurement group_id="B2" value="49.4" spread="7.8"/>
                    <measurement group_id="B3" value="54.2" spread="5.4"/>
                    <measurement group_id="B4" value="51.4" spread="10.6"/>
                    <measurement group_id="B5" value="56.4" spread="5.8"/>
                    <measurement group_id="B6" value="57.3" spread="5.8"/>
                    <measurement group_id="B7" value="54.4" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 14 days after last dose that were absent before treatment or that worsened relative to pre-treatment state.</description>
        <time_frame>Baseline (Day 1) up to 14 days after last dose of study treatment (up to 28 days)</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received PF-04937319 10 milligram (mg) tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received PF-04937319 30 mg (3 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 50 mg</title>
            <description>Participants received PF-04937319 50 mg (5 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 100 mg</title>
            <description>Participants received PF-04937319 100 mg tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 300 mg</title>
            <description>Participants received PF-04937319 300 mg (3 tablets of 100 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants received placebo matched to PF-04937319 tablet orally once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 14 days after last dose that were absent before treatment or that worsened relative to pre-treatment state.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) On Day 1</title>
        <time_frame>0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours (hrs) post morning dose on Day 1 (fasted condition)</time_frame>
        <population>Pharmacokinetic (PK) parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received PF-04937319 10 milligram (mg) tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received PF-04937319 30 mg (3 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 50 mg</title>
            <description>Participants received PF-04937319 50 mg (5 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 100 mg</title>
            <description>Participants received PF-04937319 100 mg tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 300 mg</title>
            <description>Participants received PF-04937319 300 mg (3 tablets of 100 mg) orally once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) On Day 1</title>
          <population>Pharmacokinetic (PK) parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.22" spread="25"/>
                    <measurement group_id="O2" value="69.49" spread="32"/>
                    <measurement group_id="O3" value="119.4" spread="38"/>
                    <measurement group_id="O4" value="245.4" spread="42"/>
                    <measurement group_id="O5" value="449.3" spread="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) On Day 6</title>
        <time_frame>0 (pre-dose), 0.5, 1.5, 3, 5, 8 hours post-dose on Day 6 (fed condition)</time_frame>
        <population>PK parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received PF-04937319 10 milligram (mg) tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received PF-04937319 30 mg (3 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 50 mg</title>
            <description>Participants received PF-04937319 50 mg (5 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 100 mg</title>
            <description>Participants received PF-04937319 100 mg tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 300 mg</title>
            <description>Participants received PF-04937319 300 mg (3 tablets of 100 mg) orally once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) On Day 6</title>
          <population>PK parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.73" spread="17"/>
                    <measurement group_id="O2" value="122.3" spread="17"/>
                    <measurement group_id="O3" value="234.1" spread="24"/>
                    <measurement group_id="O4" value="421.5" spread="31"/>
                    <measurement group_id="O5" value="970.6" spread="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1</title>
        <time_frame>0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 1 (fasted condition)</time_frame>
        <population>PK parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received PF-04937319 10 milligram (mg) tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received PF-04937319 30 mg (3 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 50 mg</title>
            <description>Participants received PF-04937319 50 mg (5 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 100 mg</title>
            <description>Participants received PF-04937319 100 mg tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 300 mg</title>
            <description>Participants received PF-04937319 300 mg (3 tablets of 100 mg) orally once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1</title>
          <population>PK parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="1.50" upper_limit="8.00"/>
                    <measurement group_id="O2" value="3.00" lower_limit="1.50" upper_limit="8.00"/>
                    <measurement group_id="O3" value="3.00" lower_limit="2.95" upper_limit="5.00"/>
                    <measurement group_id="O4" value="3.00" lower_limit="3.00" upper_limit="5.00"/>
                    <measurement group_id="O5" value="3.00" lower_limit="1.50" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 6</title>
        <time_frame>0 (pre-dose), 0.5, 1.5, 3, 5, 8 hours post-dose on Day 6 (fed condition)</time_frame>
        <population>PK parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest. Here ‘N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received PF-04937319 10 milligram (mg) tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received PF-04937319 30 mg (3 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 50 mg</title>
            <description>Participants received PF-04937319 50 mg (5 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 100 mg</title>
            <description>Participants received PF-04937319 100 mg tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 300 mg</title>
            <description>Participants received PF-04937319 300 mg (3 tablets of 100 mg) orally once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 6</title>
          <population>PK parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest. Here ‘N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="1.50" upper_limit="5.05"/>
                    <measurement group_id="O2" value="1.50" lower_limit="1.50" upper_limit="5.00"/>
                    <measurement group_id="O3" value="1.50" lower_limit="1.50" upper_limit="8.00"/>
                    <measurement group_id="O4" value="1.50" lower_limit="1.50" upper_limit="5.00"/>
                    <measurement group_id="O5" value="1.50" lower_limit="0.50" upper_limit="5.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) on Day 1</title>
        <description>AUCtau is the area under the plasma concentration versus time curve from time zero (pre-dose) to the end of the dosing interval (tau), here dosing interval is 24 hours.</description>
        <time_frame>0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 1 (fasted condition)</time_frame>
        <population>PK parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received PF-04937319 10 milligram (mg) tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received PF-04937319 30 mg (3 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 50 mg</title>
            <description>Participants received PF-04937319 50 mg (5 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 100 mg</title>
            <description>Participants received PF-04937319 100 mg tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 300 mg</title>
            <description>Participants received PF-04937319 300 mg (3 tablets of 100 mg) orally once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) on Day 1</title>
          <description>AUCtau is the area under the plasma concentration versus time curve from time zero (pre-dose) to the end of the dosing interval (tau), here dosing interval is 24 hours.</description>
          <population>PK parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest.</population>
          <units>nanogram*hour per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="407.0" spread="29"/>
                    <measurement group_id="O2" value="867.7" spread="21"/>
                    <measurement group_id="O3" value="1456" spread="48"/>
                    <measurement group_id="O4" value="2749" spread="38"/>
                    <measurement group_id="O5" value="6034" spread="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration at Steady State (Cmax, ss) On Day 14</title>
        <time_frame>0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 14 (fasted condition)</time_frame>
        <population>PK parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received PF-04937319 10 milligram (mg) tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received PF-04937319 30 mg (3 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 50 mg</title>
            <description>Participants received PF-04937319 50 mg (5 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 100 mg</title>
            <description>Participants received PF-04937319 100 mg tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 300 mg</title>
            <description>Participants received PF-04937319 300 mg (3 tablets of 100 mg) orally once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration at Steady State (Cmax, ss) On Day 14</title>
          <population>PK parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.09" spread="27"/>
                    <measurement group_id="O2" value="79.30" spread="31"/>
                    <measurement group_id="O3" value="171.3" spread="36"/>
                    <measurement group_id="O4" value="251.5" spread="44"/>
                    <measurement group_id="O5" value="555.9" spread="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration at Steady State (Tmax, ss) on Day 14</title>
        <time_frame>0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 14 (fasted condition)</time_frame>
        <population>PK parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received PF-04937319 10 milligram (mg) tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received PF-04937319 30 mg (3 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 50 mg</title>
            <description>Participants received PF-04937319 50 mg (5 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 100 mg</title>
            <description>Participants received PF-04937319 100 mg tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 300 mg</title>
            <description>Participants received PF-04937319 300 mg (3 tablets of 100 mg) orally once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration at Steady State (Tmax, ss) on Day 14</title>
          <population>PK parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="1.50" upper_limit="3.02"/>
                    <measurement group_id="O2" value="3.00" lower_limit="1.50" upper_limit="8.00"/>
                    <measurement group_id="O3" value="3.00" lower_limit="3.00" upper_limit="8.00"/>
                    <measurement group_id="O4" value="3.00" lower_limit="3.00" upper_limit="8.00"/>
                    <measurement group_id="O5" value="3.00" lower_limit="3.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to End of Dosing Interval at Steady State (AUCtau, ss) on Day 14</title>
        <description>AUCtau, ss = Area under the plasma concentration versus time curve from time zero (pre-dose) to the end of the dosing interval (tau) at steady state, here dosing interval is 24 hours.</description>
        <time_frame>0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 14 (fasted condition)</time_frame>
        <population>PK parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received PF-04937319 10 milligram (mg) tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received PF-04937319 30 mg (3 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 50 mg</title>
            <description>Participants received PF-04937319 50 mg (5 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 100 mg</title>
            <description>Participants received PF-04937319 100 mg tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 300 mg</title>
            <description>Participants received PF-04937319 300 mg (3 tablets of 100 mg) orally once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to End of Dosing Interval at Steady State (AUCtau, ss) on Day 14</title>
          <description>AUCtau, ss = Area under the plasma concentration versus time curve from time zero (pre-dose) to the end of the dosing interval (tau) at steady state, here dosing interval is 24 hours.</description>
          <population>PK parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
          <units>nanogram*hour per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="458.0" spread="35"/>
                    <measurement group_id="O2" value="928.7" spread="23"/>
                    <measurement group_id="O3" value="1889" spread="52"/>
                    <measurement group_id="O4" value="3167" spread="40"/>
                    <measurement group_id="O5" value="7446" spread="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Decay Half-Life (t1/2) on Day 14</title>
        <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
        <time_frame>0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24, 36, 48 hours post morning dose on Day 14 (fasted condition)</time_frame>
        <population>PK parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received PF-04937319 10 milligram (mg) tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received PF-04937319 30 mg (3 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 50 mg</title>
            <description>Participants received PF-04937319 50 mg (5 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 100 mg</title>
            <description>Participants received PF-04937319 100 mg tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 300 mg</title>
            <description>Participants received PF-04937319 300 mg (3 tablets of 100 mg) orally once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Decay Half-Life (t1/2) on Day 14</title>
          <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
          <population>PK parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.563" spread="0.77897"/>
                    <measurement group_id="O2" value="6.884" spread="1.9264"/>
                    <measurement group_id="O3" value="6.348" spread="1.4271"/>
                    <measurement group_id="O4" value="6.960" spread="1.0358"/>
                    <measurement group_id="O5" value="8.479" spread="2.4173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Minimum Observed Plasma Trough Concentration at Steady State (Cmin, ss) on Day 14</title>
        <time_frame>0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16 hours post morning dose on Day 14 (fasted condition)</time_frame>
        <population>PK parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received PF-04937319 10 milligram (mg) tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received PF-04937319 30 mg (3 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 50 mg</title>
            <description>Participants received PF-04937319 50 mg (5 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 100 mg</title>
            <description>Participants received PF-04937319 100 mg tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 300 mg</title>
            <description>Participants received PF-04937319 300 mg (3 tablets of 100 mg) orally once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Observed Plasma Trough Concentration at Steady State (Cmin, ss) on Day 14</title>
          <population>PK parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.380" spread="83"/>
                    <measurement group_id="O2" value="10.56" spread="43"/>
                    <measurement group_id="O3" value="22.73" spread="103"/>
                    <measurement group_id="O4" value="41.68" spread="64"/>
                    <measurement group_id="O5" value="129.8" spread="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Unchanged Drug Excreted in the Urine Over Dosing Interval (Ae[%]) on Day 14</title>
        <description>Percentage of drug excreted unchanged in urine calculated as overall amount of unchanged drug excreted in the urine over the dosing interval (24 hours) divided by total daily dose multiplied by 100.</description>
        <time_frame>0 hour (pre-dose) through 24 hours post-dose on Day 14</time_frame>
        <population>PK parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received PF-04937319 10 milligram (mg) tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received PF-04937319 30 mg (3 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 50 mg</title>
            <description>Participants received PF-04937319 50 mg (5 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 100 mg</title>
            <description>Participants received PF-04937319 100 mg tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 300 mg</title>
            <description>Participants received PF-04937319 300 mg (3 tablets of 100 mg) orally once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Unchanged Drug Excreted in the Urine Over Dosing Interval (Ae[%]) on Day 14</title>
          <description>Percentage of drug excreted unchanged in urine calculated as overall amount of unchanged drug excreted in the urine over the dosing interval (24 hours) divided by total daily dose multiplied by 100.</description>
          <population>PK parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
          <units>percentage of dose</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3904" spread="0.11901"/>
                    <measurement group_id="O2" value="0.3533" spread="0.20183"/>
                    <measurement group_id="O3" value="0.6463" spread="0.56717"/>
                    <measurement group_id="O4" value="0.5380" spread="0.34593"/>
                    <measurement group_id="O5" value="0.4294" spread="0.44676"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Oral Clearance (CL/F) on Day 14</title>
        <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
        <time_frame>0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 14 (fasted condition)</time_frame>
        <population>PK parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received PF-04937319 10 milligram (mg) tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received PF-04937319 30 mg (3 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 50 mg</title>
            <description>Participants received PF-04937319 50 mg (5 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 100 mg</title>
            <description>Participants received PF-04937319 100 mg tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 300 mg</title>
            <description>Participants received PF-04937319 300 mg (3 tablets of 100 mg) orally once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Oral Clearance (CL/F) on Day 14</title>
          <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
          <population>PK parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
          <units>liter per hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.86" spread="25"/>
                    <measurement group_id="O2" value="32.32" spread="23"/>
                    <measurement group_id="O3" value="26.48" spread="34"/>
                    <measurement group_id="O4" value="31.56" spread="37"/>
                    <measurement group_id="O5" value="40.29" spread="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Volume of Distribution (Vz/F) on Day 14</title>
        <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.</description>
        <time_frame>0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 14 (fasted condition)</time_frame>
        <population>PK parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received PF-04937319 10 milligram (mg) tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received PF-04937319 30 mg (3 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 50 mg</title>
            <description>Participants received PF-04937319 50 mg (5 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 100 mg</title>
            <description>Participants received PF-04937319 100 mg tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 300 mg</title>
            <description>Participants received PF-04937319 300 mg (3 tablets of 100 mg) orally once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vz/F) on Day 14</title>
          <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.</description>
          <population>PK parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
          <units>liter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205.3" spread="20"/>
                    <measurement group_id="O2" value="311.6" spread="32"/>
                    <measurement group_id="O3" value="236.7" spread="27"/>
                    <measurement group_id="O4" value="314.0" spread="28"/>
                    <measurement group_id="O5" value="475.2" spread="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Observed Accumulation Ratio for AUCtau (Rac)</title>
        <description>Accumulation ratio for AUCtau (Rac) was calculated as area under the curve from time zero to end of dosing interval (AUCtau) on Day 14 divided by area under the curve from time zero to end of dosing interval (AUCtau) on Day 1. Dosing interval = 24 hours.</description>
        <time_frame>0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 1 and Day 14 (fasted condition)</time_frame>
        <population>PK parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received PF-04937319 10 milligram (mg) tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received PF-04937319 30 mg (3 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 50 mg</title>
            <description>Participants received PF-04937319 50 mg (5 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 100 mg</title>
            <description>Participants received PF-04937319 100 mg tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 300 mg</title>
            <description>Participants received PF-04937319 300 mg (3 tablets of 100 mg) orally once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Accumulation Ratio for AUCtau (Rac)</title>
          <description>Accumulation ratio for AUCtau (Rac) was calculated as area under the curve from time zero to end of dosing interval (AUCtau) on Day 14 divided by area under the curve from time zero to end of dosing interval (AUCtau) on Day 1. Dosing interval = 24 hours.</description>
          <population>PK parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.204" spread="22"/>
                    <measurement group_id="O2" value="1.069" spread="15"/>
                    <measurement group_id="O3" value="1.296" spread="24"/>
                    <measurement group_id="O4" value="1.152" spread="22"/>
                    <measurement group_id="O5" value="1.118" spread="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Observed Accumulation Ratio for Cmax (Rac, Cmax)</title>
        <description>Accumulation ratio for Cmax (Rac, Cmax) was calculated as maximum observed plasma concentration (Cmax) on Day 14 divided by maximum observed plasma concentration (Cmax) on Day 1.</description>
        <time_frame>0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 1 and Day 14 (fasted condition)</time_frame>
        <population>PK parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received PF-04937319 10 milligram (mg) tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received PF-04937319 30 mg (3 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 50 mg</title>
            <description>Participants received PF-04937319 50 mg (5 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 100 mg</title>
            <description>Participants received PF-04937319 100 mg tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 300 mg</title>
            <description>Participants received PF-04937319 300 mg (3 tablets of 100 mg) orally once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Accumulation Ratio for Cmax (Rac, Cmax)</title>
          <description>Accumulation ratio for Cmax (Rac, Cmax) was calculated as maximum observed plasma concentration (Cmax) on Day 14 divided by maximum observed plasma concentration (Cmax) on Day 1.</description>
          <population>PK parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.414" spread="41"/>
                    <measurement group_id="O2" value="1.141" spread="28"/>
                    <measurement group_id="O3" value="1.437" spread="17"/>
                    <measurement group_id="O4" value="1.026" spread="25"/>
                    <measurement group_id="O5" value="1.080" spread="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1</title>
        <description>Percent change from baseline in area under the plasma glucose concentration-time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC. Baseline value was the AUC (2-6) calculated on Day -1.</description>
        <time_frame>-46, -45.75, -45.5, -45, -44.5, -44, -43, -42 hrs pre-dose on Day -1; 2, 2.25, 2.5, 3, 3.5, 4, 5, 6 hrs post-dose on Day 1 (fasted condition)</time_frame>
        <population>Pharmacodynamic (PD) analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 PD parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received PF-04937319 10 milligram (mg) tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received PF-04937319 30 mg (3 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 50 mg</title>
            <description>Participants received PF-04937319 50 mg (5 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 100 mg</title>
            <description>Participants received PF-04937319 100 mg tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 300 mg</title>
            <description>Participants received PF-04937319 300 mg (3 tablets of 100 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants received placebo matched to PF-04937319 tablet orally once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1</title>
          <description>Percent change from baseline in area under the plasma glucose concentration-time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC. Baseline value was the AUC (2-6) calculated on Day -1.</description>
          <population>Pharmacodynamic (PD) analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 PD parameter.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="8.881"/>
                    <measurement group_id="O2" value="-2.67" spread="6.670"/>
                    <measurement group_id="O3" value="6.41" spread="14.532"/>
                    <measurement group_id="O4" value="-12.11" spread="14.225"/>
                    <measurement group_id="O5" value="-12.29" spread="13.711"/>
                    <measurement group_id="O6" value="-3.71" spread="10.848"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 14</title>
        <description>Percent change from baseline in area under the plasma glucose concentration-time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC. Baseline value was the AUC (2-6) calculated on Day -1.</description>
        <time_frame>-46, -45.75, -45.5, -45, -44.5, -44, -43, -42 hrs pre-dose on Day -1; 2, 2.25, 2.5, 3, 3.5, 4, 5, 6 hrs post-dose on Day 14 (fasted condition)</time_frame>
        <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 PD parameter. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received PF-04937319 10 milligram (mg) tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received PF-04937319 30 mg (3 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 50 mg</title>
            <description>Participants received PF-04937319 50 mg (5 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 100 mg</title>
            <description>Participants received PF-04937319 100 mg tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 300 mg</title>
            <description>Participants received PF-04937319 300 mg (3 tablets of 100 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants received placebo matched to PF-04937319 tablet orally once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 14</title>
          <description>Percent change from baseline in area under the plasma glucose concentration-time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC. Baseline value was the AUC (2-6) calculated on Day -1.</description>
          <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 PD parameter. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.94" spread="15.477"/>
                    <measurement group_id="O2" value="-4.91" spread="16.601"/>
                    <measurement group_id="O3" value="-4.11" spread="17.321"/>
                    <measurement group_id="O4" value="-26.83" spread="21.054"/>
                    <measurement group_id="O5" value="-11.37" spread="15.205"/>
                    <measurement group_id="O6" value="-2.86" spread="12.103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Insulin Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14</title>
        <description>Percent change from baseline in area under the plasma insulin concentration-time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC. Baseline value was the AUC (2-6) calculated on Day -1.</description>
        <time_frame>-46, -45.75, -45.5, -45, -44.5, -44, -43, -42 hrs pre-dose on Day -1; 2, 2.25, 2.5, 3, 3.5, 4, 5, 6 hrs post-dose on Day 1 and 14 (fasted condition)</time_frame>
        <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 PD parameter. Here 'n' signifies participants evaluable for this measure at specified time point for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received PF-04937319 10 milligram (mg) tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received PF-04937319 30 mg (3 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 50 mg</title>
            <description>Participants received PF-04937319 50 mg (5 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 100 mg</title>
            <description>Participants received PF-04937319 100 mg tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 300 mg</title>
            <description>Participants received PF-04937319 300 mg (3 tablets of 100 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants received placebo matched to PF-04937319 tablet orally once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Insulin Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14</title>
          <description>Percent change from baseline in area under the plasma insulin concentration-time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC. Baseline value was the AUC (2-6) calculated on Day -1.</description>
          <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 PD parameter. Here 'n' signifies participants evaluable for this measure at specified time point for each arm group, respectively.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent Change at Day 1 (n=9,9,9,9,9,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.22" spread="17.843"/>
                    <measurement group_id="O2" value="13.24" spread="22.221"/>
                    <measurement group_id="O3" value="24.11" spread="13.772"/>
                    <measurement group_id="O4" value="4.41" spread="17.470"/>
                    <measurement group_id="O5" value="18.10" spread="17.059"/>
                    <measurement group_id="O6" value="-2.92" spread="15.768"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change at Day 14 (n=8,9,9,9,7,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.77" spread="21.452"/>
                    <measurement group_id="O2" value="17.98" spread="26.499"/>
                    <measurement group_id="O3" value="30.86" spread="41.063"/>
                    <measurement group_id="O4" value="0.38" spread="21.140"/>
                    <measurement group_id="O5" value="39.23" spread="26.876"/>
                    <measurement group_id="O6" value="7.62" spread="26.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in C-peptide Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14</title>
        <description>Percent change from baseline in area under the plasma C-peptide concentration-time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC. Baseline value was the AUC (2-6) calculated on Day -1.</description>
        <time_frame>-46, -45.75, -45.5, -45, -44.5, -44, -43, -42 hrs pre-dose on Day -1; 2, 2.25, 2.5, 3, 3.5, 4, 5, 6 hrs post-dose on Day 1 and 14 (fasted condition)</time_frame>
        <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 PD parameter. Here 'n' signifies participants evaluable for this measure at specified time point for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received PF-04937319 10 milligram (mg) tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received PF-04937319 30 mg (3 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 50 mg</title>
            <description>Participants received PF-04937319 50 mg (5 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 100 mg</title>
            <description>Participants received PF-04937319 100 mg tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 300 mg</title>
            <description>Participants received PF-04937319 300 mg (3 tablets of 100 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants received placebo matched to PF-04937319 tablet orally once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in C-peptide Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14</title>
          <description>Percent change from baseline in area under the plasma C-peptide concentration-time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC. Baseline value was the AUC (2-6) calculated on Day -1.</description>
          <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 PD parameter. Here 'n' signifies participants evaluable for this measure at specified time point for each arm group, respectively.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent Change at Day 1 (n=9,9,9,9,9,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.36" spread="10.170"/>
                    <measurement group_id="O2" value="8.53" spread="13.383"/>
                    <measurement group_id="O3" value="12.65" spread="9.974"/>
                    <measurement group_id="O4" value="2.37" spread="12.421"/>
                    <measurement group_id="O5" value="16.34" spread="8.940"/>
                    <measurement group_id="O6" value="-1.43" spread="9.488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change at Day 14 (n=8,9,9,9,7,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.66" spread="11.069"/>
                    <measurement group_id="O2" value="13.49" spread="14.403"/>
                    <measurement group_id="O3" value="16.51" spread="27.962"/>
                    <measurement group_id="O4" value="-1.44" spread="14.463"/>
                    <measurement group_id="O5" value="22.50" spread="14.809"/>
                    <measurement group_id="O6" value="1.80" spread="16.722"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Average Plasma Glucose at Day 1, 6, 14</title>
        <description>Glucometer testing performed by finger-stick at 8 time points per day to measure glucose levels. Average plasma glucose was calculated as area under the plasma glucose concentration-time curve from 0 to 24 hours (AUC [0-24]) divided by 24.</description>
        <time_frame>-46, -44, -42, -40, -38, -36, -30, -27 hrs pre-dose on Day -1; 2, 6, 8, 10, 12,18,21 hrs post-dose on Day 1, 6 and 14; additional 0 hr (pre-dose) on Day 6 and 4 hr post-dose on Day 1 and 14</time_frame>
        <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 PD parameter. Here 'n' signifies participants evaluable for this measure at specified time point for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received PF-04937319 10 milligram (mg) tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received PF-04937319 30 mg (3 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 50 mg</title>
            <description>Participants received PF-04937319 50 mg (5 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 100 mg</title>
            <description>Participants received PF-04937319 100 mg tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 300 mg</title>
            <description>Participants received PF-04937319 300 mg (3 tablets of 100 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants received placebo matched to PF-04937319 tablet orally once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Plasma Glucose at Day 1, 6, 14</title>
          <description>Glucometer testing performed by finger-stick at 8 time points per day to measure glucose levels. Average plasma glucose was calculated as area under the plasma glucose concentration-time curve from 0 to 24 hours (AUC [0-24]) divided by 24.</description>
          <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 PD parameter. Here 'n' signifies participants evaluable for this measure at specified time point for each arm group, respectively.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=9,9,9,9,9,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192.10" spread="22.913"/>
                    <measurement group_id="O2" value="188.83" spread="48.992"/>
                    <measurement group_id="O3" value="195.78" spread="37.871"/>
                    <measurement group_id="O4" value="205.38" spread="44.632"/>
                    <measurement group_id="O5" value="170.95" spread="51.465"/>
                    <measurement group_id="O6" value="189.07" spread="39.131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 1 (n=9,9,9,9,9,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.18" spread="9.851"/>
                    <measurement group_id="O2" value="-5.24" spread="6.421"/>
                    <measurement group_id="O3" value="8.72" spread="15.071"/>
                    <measurement group_id="O4" value="-1.90" spread="21.784"/>
                    <measurement group_id="O5" value="-23.26" spread="19.189"/>
                    <measurement group_id="O6" value="3.04" spread="17.611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 6 (n=8,9,9,9,7,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.62" spread="16.247"/>
                    <measurement group_id="O2" value="-6.35" spread="22.496"/>
                    <measurement group_id="O3" value="9.80" spread="30.359"/>
                    <measurement group_id="O4" value="-32.36" spread="24.121"/>
                    <measurement group_id="O5" value="-47.19" spread="25.752"/>
                    <measurement group_id="O6" value="3.92" spread="17.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 14 (n=8,9,9,9,7,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.65" spread="25.918"/>
                    <measurement group_id="O2" value="-16.45" spread="27.709"/>
                    <measurement group_id="O3" value="-14.79" spread="33.687"/>
                    <measurement group_id="O4" value="-48.87" spread="27.216"/>
                    <measurement group_id="O5" value="-34.15" spread="24.596"/>
                    <measurement group_id="O6" value="-7.48" spread="21.703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15</title>
        <time_frame>Baseline (Pre-dose on Day 1), Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15</time_frame>
        <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 PD parameter. Here 'n' signifies participants evaluable for this measure at specified time point for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received PF-04937319 10 milligram (mg) tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received PF-04937319 30 mg (3 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 50 mg</title>
            <description>Participants received PF-04937319 50 mg (5 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 100 mg</title>
            <description>Participants received PF-04937319 100 mg tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 300 mg</title>
            <description>Participants received PF-04937319 300 mg (3 tablets of 100 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants received placebo matched to PF-04937319 tablet orally once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15</title>
          <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 PD parameter. Here 'n' signifies participants evaluable for this measure at specified time point for each arm group, respectively.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=9,9,9,9,9,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173.78" spread="31.952"/>
                    <measurement group_id="O2" value="181.33" spread="50.621"/>
                    <measurement group_id="O3" value="190.11" spread="34.505"/>
                    <measurement group_id="O4" value="193.67" spread="45.695"/>
                    <measurement group_id="O5" value="162.33" spread="50.269"/>
                    <measurement group_id="O6" value="172.44" spread="42.527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 2 (n=9,9,9,9,9,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.00" spread="10.840"/>
                    <measurement group_id="O2" value="-4.67" spread="12.845"/>
                    <measurement group_id="O3" value="-6.78" spread="25.430"/>
                    <measurement group_id="O4" value="-1.78" spread="14.507"/>
                    <measurement group_id="O5" value="-23.44" spread="18.662"/>
                    <measurement group_id="O6" value="0.94" spread="12.588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 3 (n=9,9,9,9,9,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.11" spread="10.216"/>
                    <measurement group_id="O2" value="-5.78" spread="10.171"/>
                    <measurement group_id="O3" value="-18.78" spread="27.124"/>
                    <measurement group_id="O4" value="-13.22" spread="15.571"/>
                    <measurement group_id="O5" value="-32.78" spread="17.527"/>
                    <measurement group_id="O6" value="-7.81" spread="16.885"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 4 (n=9,9,9,9,8,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.44" spread="19.603"/>
                    <measurement group_id="O2" value="-9.44" spread="16.001"/>
                    <measurement group_id="O3" value="-13.78" spread="28.900"/>
                    <measurement group_id="O4" value="-19.67" spread="20.899"/>
                    <measurement group_id="O5" value="-42.88" spread="20.972"/>
                    <measurement group_id="O6" value="-4.13" spread="18.722"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 5 (n=9,9,9,9,9,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.67" spread="16.256"/>
                    <measurement group_id="O2" value="-9.89" spread="15.358"/>
                    <measurement group_id="O3" value="-22.56" spread="29.560"/>
                    <measurement group_id="O4" value="-26.56" spread="21.030"/>
                    <measurement group_id="O5" value="-30.33" spread="22.170"/>
                    <measurement group_id="O6" value="-14.06" spread="21.402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 6 (n=9,9,9,9,7,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.89" spread="18.210"/>
                    <measurement group_id="O2" value="-16.33" spread="17.804"/>
                    <measurement group_id="O3" value="-18.00" spread="34.380"/>
                    <measurement group_id="O4" value="-29.11" spread="16.027"/>
                    <measurement group_id="O5" value="-43.00" spread="15.610"/>
                    <measurement group_id="O6" value="-8.27" spread="12.708"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 7 (n=8,9,9,9,7,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.50" spread="21.314"/>
                    <measurement group_id="O2" value="-12.78" spread="13.664"/>
                    <measurement group_id="O3" value="-14.44" spread="37.270"/>
                    <measurement group_id="O4" value="-30.22" spread="16.672"/>
                    <measurement group_id="O5" value="-43.71" spread="18.117"/>
                    <measurement group_id="O6" value="-5.60" spread="12.704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 8 (n=8,9,9,9,7,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.25" spread="21.212"/>
                    <measurement group_id="O2" value="-8.56" spread="20.415"/>
                    <measurement group_id="O3" value="-5.56" spread="37.964"/>
                    <measurement group_id="O4" value="-24.11" spread="19.934"/>
                    <measurement group_id="O5" value="-31.71" spread="20.155"/>
                    <measurement group_id="O6" value="-4.93" spread="16.434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 9 (n=8,9,9,9,7,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.63" spread="20.784"/>
                    <measurement group_id="O2" value="-22.11" spread="20.709"/>
                    <measurement group_id="O3" value="-9.78" spread="42.825"/>
                    <measurement group_id="O4" value="-24.78" spread="17.817"/>
                    <measurement group_id="O5" value="-38.00" spread="19.502"/>
                    <measurement group_id="O6" value="-2.80" spread="15.857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 10 (n=8,9,9,9,7,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.88" spread="23.503"/>
                    <measurement group_id="O2" value="-16.89" spread="20.847"/>
                    <measurement group_id="O3" value="-16.33" spread="32.427"/>
                    <measurement group_id="O4" value="-37.11" spread="19.877"/>
                    <measurement group_id="O5" value="-34.29" spread="24.452"/>
                    <measurement group_id="O6" value="-6.20" spread="10.544"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 11 (n=8,9,9,9,7,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.38" spread="28.540"/>
                    <measurement group_id="O2" value="-22.56" spread="22.490"/>
                    <measurement group_id="O3" value="-18.11" spread="39.810"/>
                    <measurement group_id="O4" value="-32.89" spread="20.294"/>
                    <measurement group_id="O5" value="-38.57" spread="22.240"/>
                    <measurement group_id="O6" value="-5.73" spread="19.374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 12 (n=8,9,9,9,7,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.13" spread="28.423"/>
                    <measurement group_id="O2" value="-18.56" spread="28.183"/>
                    <measurement group_id="O3" value="-16.89" spread="41.870"/>
                    <measurement group_id="O4" value="-32.22" spread="17.880"/>
                    <measurement group_id="O5" value="-43.57" spread="26.576"/>
                    <measurement group_id="O6" value="-7.73" spread="17.910"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 13 (n=8,9,9,9,7,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.13" spread="30.258"/>
                    <measurement group_id="O2" value="-23.44" spread="23.807"/>
                    <measurement group_id="O3" value="-24.78" spread="40.822"/>
                    <measurement group_id="O4" value="-30.89" spread="19.548"/>
                    <measurement group_id="O5" value="-39.71" spread="22.706"/>
                    <measurement group_id="O6" value="-12.27" spread="18.718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 14 (n=8,9,9,9,7,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.63" spread="26.175"/>
                    <measurement group_id="O2" value="-23.67" spread="25.441"/>
                    <measurement group_id="O3" value="-26.56" spread="39.768"/>
                    <measurement group_id="O4" value="-43.78" spread="22.725"/>
                    <measurement group_id="O5" value="-41.86" spread="22.386"/>
                    <measurement group_id="O6" value="-11.80" spread="16.545"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 15 (n=8,9,9,9,7,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.38" spread="22.595"/>
                    <measurement group_id="O2" value="-21.44" spread="26.034"/>
                    <measurement group_id="O3" value="-23.89" spread="38.238"/>
                    <measurement group_id="O4" value="-44.11" spread="19.586"/>
                    <measurement group_id="O5" value="-40.57" spread="25.553"/>
                    <measurement group_id="O6" value="-11.47" spread="17.916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up</title>
        <description>Blood sample for lipid biomarker was taken following 12-hours fasting. Baseline value was collected on Day -2 for lipids.</description>
        <time_frame>Baseline (Day -2), Day 3, 6, 10, 14, 16 and Follow-up (7 to 14 days after last dose of study medication)</time_frame>
        <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 PD parameter. Here 'n' signifies participants evaluable for this measure at specified time point for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received PF-04937319 10 milligram (mg) tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received PF-04937319 30 mg (3 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 50 mg</title>
            <description>Participants received PF-04937319 50 mg (5 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 100 mg</title>
            <description>Participants received PF-04937319 100 mg tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 300 mg</title>
            <description>Participants received PF-04937319 300 mg (3 tablets of 100 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants received placebo matched to PF-04937319 tablet orally once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up</title>
          <description>Blood sample for lipid biomarker was taken following 12-hours fasting. Baseline value was collected on Day -2 for lipids.</description>
          <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 PD parameter. Here 'n' signifies participants evaluable for this measure at specified time point for each arm group, respectively.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=9,9,9,9,9,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178.89" spread="63.21"/>
                    <measurement group_id="O2" value="152.33" spread="43.88"/>
                    <measurement group_id="O3" value="175.56" spread="53.32"/>
                    <measurement group_id="O4" value="192.78" spread="91.62"/>
                    <measurement group_id="O5" value="123.33" spread="47.89"/>
                    <measurement group_id="O6" value="152.31" spread="70.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 3 (n=9,9,9,9,9,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.89" spread="82.19"/>
                    <measurement group_id="O2" value="1.67" spread="63.16"/>
                    <measurement group_id="O3" value="-44.44" spread="45.88"/>
                    <measurement group_id="O4" value="-25.44" spread="59.99"/>
                    <measurement group_id="O5" value="0.22" spread="42.40"/>
                    <measurement group_id="O6" value="0.88" spread="47.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 6 (n=9,9,9,9,7,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.00" spread="70.40"/>
                    <measurement group_id="O2" value="-1.33" spread="65.02"/>
                    <measurement group_id="O3" value="-40.44" spread="50.85"/>
                    <measurement group_id="O4" value="-29.00" spread="62.90"/>
                    <measurement group_id="O5" value="13.14" spread="51.50"/>
                    <measurement group_id="O6" value="-14.67" spread="51.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 10 (n=8,9,9,9,7,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.88" spread="58.15"/>
                    <measurement group_id="O2" value="1.78" spread="66.28"/>
                    <measurement group_id="O3" value="-6.44" spread="59.39"/>
                    <measurement group_id="O4" value="-13.56" spread="51.83"/>
                    <measurement group_id="O5" value="30.71" spread="43.77"/>
                    <measurement group_id="O6" value="2.13" spread="46.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 14 (n=8,9,9,9,7,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.25" spread="76.20"/>
                    <measurement group_id="O2" value="-4.44" spread="65.79"/>
                    <measurement group_id="O3" value="-37.33" spread="48.75"/>
                    <measurement group_id="O4" value="-40.33" spread="55.72"/>
                    <measurement group_id="O5" value="15.57" spread="38.25"/>
                    <measurement group_id="O6" value="-21.67" spread="44.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 16 (n=8,9,9,9,7,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.25" spread="108.99"/>
                    <measurement group_id="O2" value="-6.67" spread="80.27"/>
                    <measurement group_id="O3" value="-36.22" spread="50.27"/>
                    <measurement group_id="O4" value="-35.33" spread="53.61"/>
                    <measurement group_id="O5" value="23.57" spread="50.04"/>
                    <measurement group_id="O6" value="-19.07" spread="47.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Follow-up (n=9,9,9,9,7,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.22" spread="73.73"/>
                    <measurement group_id="O2" value="38.78" spread="163.30"/>
                    <measurement group_id="O3" value="4.56" spread="73.52"/>
                    <measurement group_id="O4" value="-45.44" spread="120.43"/>
                    <measurement group_id="O5" value="22.29" spread="57.79"/>
                    <measurement group_id="O6" value="1.94" spread="52.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up</title>
        <description>Blood sample for lipid biomarker was taken following 12-hours fasting. Baseline value was collected on Day -2 for lipids.</description>
        <time_frame>Baseline (Day -2), Day 3, 6, 10, 14, 16 and Follow-up (7 to 14 days after last dose of study medication)</time_frame>
        <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 PD parameter. Here 'n' signifies participants evaluable for this measure at specified time point for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received PF-04937319 10 milligram (mg) tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received PF-04937319 30 mg (3 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 50 mg</title>
            <description>Participants received PF-04937319 50 mg (5 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 100 mg</title>
            <description>Participants received PF-04937319 100 mg tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 300 mg</title>
            <description>Participants received PF-04937319 300 mg (3 tablets of 100 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants received placebo matched to PF-04937319 tablet orally once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up</title>
          <description>Blood sample for lipid biomarker was taken following 12-hours fasting. Baseline value was collected on Day -2 for lipids.</description>
          <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 PD parameter. Here 'n' signifies participants evaluable for this measure at specified time point for each arm group, respectively.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=9,9,9,9,9,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200.56" spread="34.32"/>
                    <measurement group_id="O2" value="207.33" spread="41.11"/>
                    <measurement group_id="O3" value="205.00" spread="50.52"/>
                    <measurement group_id="O4" value="213.22" spread="53.38"/>
                    <measurement group_id="O5" value="170.22" spread="41.37"/>
                    <measurement group_id="O6" value="181.94" spread="34.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 3 (n=9,9,9,9,9,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.00" spread="17.21"/>
                    <measurement group_id="O2" value="-9.33" spread="13.46"/>
                    <measurement group_id="O3" value="-14.22" spread="16.93"/>
                    <measurement group_id="O4" value="-16.33" spread="18.33"/>
                    <measurement group_id="O5" value="-11.56" spread="31.13"/>
                    <measurement group_id="O6" value="-7.50" spread="18.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 6 (n=9,9,9,9,7,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.11" spread="20.95"/>
                    <measurement group_id="O2" value="-25.11" spread="19.47"/>
                    <measurement group_id="O3" value="-20.78" spread="19.39"/>
                    <measurement group_id="O4" value="-11.33" spread="21.17"/>
                    <measurement group_id="O5" value="0.00" spread="42.90"/>
                    <measurement group_id="O6" value="-6.47" spread="26.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 10 (n=8,9,9,9,7,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.00" spread="24.51"/>
                    <measurement group_id="O2" value="-14.67" spread="14.40"/>
                    <measurement group_id="O3" value="-30.89" spread="17.41"/>
                    <measurement group_id="O4" value="-15.11" spread="20.76"/>
                    <measurement group_id="O5" value="-2.29" spread="41.43"/>
                    <measurement group_id="O6" value="0.33" spread="30.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 14 (n=8,9,9,9,7,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.50" spread="21.08"/>
                    <measurement group_id="O2" value="-29.11" spread="14.42"/>
                    <measurement group_id="O3" value="-27.44" spread="17.08"/>
                    <measurement group_id="O4" value="-24.22" spread="25.73"/>
                    <measurement group_id="O5" value="1.29" spread="41.63"/>
                    <measurement group_id="O6" value="-6.60" spread="37.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 16 (n=8,9,9,9,7,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.38" spread="26.72"/>
                    <measurement group_id="O2" value="-22.11" spread="13.60"/>
                    <measurement group_id="O3" value="-29.11" spread="20.26"/>
                    <measurement group_id="O4" value="-12.11" spread="24.49"/>
                    <measurement group_id="O5" value="1.86" spread="45.05"/>
                    <measurement group_id="O6" value="-1.43" spread="32.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Follow-up (n=9,9,9,9,7,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.44" spread="25.73"/>
                    <measurement group_id="O2" value="-12.44" spread="24.70"/>
                    <measurement group_id="O3" value="-29.44" spread="27.13"/>
                    <measurement group_id="O4" value="-33.56" spread="40.73"/>
                    <measurement group_id="O5" value="-15.29" spread="8.24"/>
                    <measurement group_id="O6" value="-5.50" spread="29.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up</title>
        <description>Blood sample for lipid biomarker was taken following 12-hours fasting. Baseline value was collected on Day -2 for lipids.</description>
        <time_frame>Baseline (Day -2), Day 3, 6, 10, 14, 16 and Follow-up (7 to 14 days after last dose of study medication)</time_frame>
        <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 PD parameter. Here 'n' signifies participants evaluable for this measure at specified time point for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received PF-04937319 10 milligram (mg) tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received PF-04937319 30 mg (3 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 50 mg</title>
            <description>Participants received PF-04937319 50 mg (5 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 100 mg</title>
            <description>Participants received PF-04937319 100 mg tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 300 mg</title>
            <description>Participants received PF-04937319 300 mg (3 tablets of 100 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants received placebo matched to PF-04937319 tablet orally once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up</title>
          <description>Blood sample for lipid biomarker was taken following 12-hours fasting. Baseline value was collected on Day -2 for lipids.</description>
          <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 PD parameter. Here 'n' signifies participants evaluable for this measure at specified time point for each arm group, respectively.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=9,9,9,9,9,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.67" spread="37.41"/>
                    <measurement group_id="O2" value="133.56" spread="43.47"/>
                    <measurement group_id="O3" value="123.44" spread="35.72"/>
                    <measurement group_id="O4" value="130.67" spread="33.83"/>
                    <measurement group_id="O5" value="96.11" spread="37.88"/>
                    <measurement group_id="O6" value="102.44" spread="31.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 3 (n=9,9,9,9,9,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.22" spread="22.22"/>
                    <measurement group_id="O2" value="-5.89" spread="19.37"/>
                    <measurement group_id="O3" value="-6.89" spread="15.26"/>
                    <measurement group_id="O4" value="-6.67" spread="19.46"/>
                    <measurement group_id="O5" value="-11.00" spread="23.51"/>
                    <measurement group_id="O6" value="-3.63" spread="14.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 6 (n=9,9,9,9,7,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.78" spread="23.21"/>
                    <measurement group_id="O2" value="-20.44" spread="22.32"/>
                    <measurement group_id="O3" value="-13.67" spread="14.74"/>
                    <measurement group_id="O4" value="-2.33" spread="22.11"/>
                    <measurement group_id="O5" value="-0.29" spread="38.98"/>
                    <measurement group_id="O6" value="2.73" spread="20.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 10 (n=8,9,9,9,7,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.00" spread="24.94"/>
                    <measurement group_id="O2" value="-11.44" spread="16.84"/>
                    <measurement group_id="O3" value="-30.89" spread="14.08"/>
                    <measurement group_id="O4" value="-7.89" spread="17.92"/>
                    <measurement group_id="O5" value="-9.57" spread="35.69"/>
                    <measurement group_id="O6" value="5.07" spread="24.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 14 (n=8,9,9,9,7,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.13" spread="21.14"/>
                    <measurement group_id="O2" value="-22.44" spread="16.49"/>
                    <measurement group_id="O3" value="-19.89" spread="14.68"/>
                    <measurement group_id="O4" value="-11.56" spread="17.92"/>
                    <measurement group_id="O5" value="-1.00" spread="38.18"/>
                    <measurement group_id="O6" value="4.80" spread="30.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 16 (n=8,9,9,9,7,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.88" spread="22.22"/>
                    <measurement group_id="O2" value="-15.00" spread="14.11"/>
                    <measurement group_id="O3" value="-20.22" spread="16.75"/>
                    <measurement group_id="O4" value="-0.67" spread="16.86"/>
                    <measurement group_id="O5" value="-3.86" spread="38.21"/>
                    <measurement group_id="O6" value="5.79" spread="27.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Follow-up (n=9,8,9,9,7,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.22" spread="24.40"/>
                    <measurement group_id="O2" value="-10.38" spread="15.15"/>
                    <measurement group_id="O3" value="-27.11" spread="22.05"/>
                    <measurement group_id="O4" value="-19.78" spread="22.97"/>
                    <measurement group_id="O5" value="-17.43" spread="16.70"/>
                    <measurement group_id="O6" value="-2.25" spread="23.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up</title>
        <description>Blood sample for lipid biomarker was taken following 12-hours fasting. Baseline value was collected on Day -2 for lipids.</description>
        <time_frame>Baseline (Day -2), Day 3, 6, 10, 14, 16 and Follow-up (7 to 14 days after last dose of study medication)</time_frame>
        <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 PD parameter. Here 'n' signifies participants evaluable for this measure at specified time point for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received PF-04937319 10 milligram (mg) tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received PF-04937319 30 mg (3 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 50 mg</title>
            <description>Participants received PF-04937319 50 mg (5 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 100 mg</title>
            <description>Participants received PF-04937319 100 mg tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 300 mg</title>
            <description>Participants received PF-04937319 300 mg (3 tablets of 100 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants received placebo matched to PF-04937319 tablet orally once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up</title>
          <description>Blood sample for lipid biomarker was taken following 12-hours fasting. Baseline value was collected on Day -2 for lipids.</description>
          <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 PD parameter. Here 'n' signifies participants evaluable for this measure at specified time point for each arm group, respectively.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=9,9,9,9,9,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.11" spread="10.96"/>
                    <measurement group_id="O2" value="43.33" spread="9.51"/>
                    <measurement group_id="O3" value="46.44" spread="11.51"/>
                    <measurement group_id="O4" value="43.89" spread="13.66"/>
                    <measurement group_id="O5" value="49.44" spread="14.05"/>
                    <measurement group_id="O6" value="48.94" spread="9.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 3 (n=9,9,9,9,9,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.56" spread="4.10"/>
                    <measurement group_id="O2" value="-3.67" spread="6.36"/>
                    <measurement group_id="O3" value="1.33" spread="6.75"/>
                    <measurement group_id="O4" value="-4.56" spread="4.07"/>
                    <measurement group_id="O5" value="-0.67" spread="7.07"/>
                    <measurement group_id="O6" value="-3.88" spread="8.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 6 (n=9,9,9,9,7,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.00" spread="2.65"/>
                    <measurement group_id="O2" value="-4.33" spread="7.73"/>
                    <measurement group_id="O3" value="1.00" spread="4.66"/>
                    <measurement group_id="O4" value="-3.11" spread="3.69"/>
                    <measurement group_id="O5" value="-2.43" spread="2.64"/>
                    <measurement group_id="O6" value="-6.20" spread="7.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 10 (n=8,9,9,9,7,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.63" spread="4.21"/>
                    <measurement group_id="O2" value="-3.44" spread="5.98"/>
                    <measurement group_id="O3" value="1.22" spread="5.70"/>
                    <measurement group_id="O4" value="-4.44" spread="3.21"/>
                    <measurement group_id="O5" value="1.14" spread="4.49"/>
                    <measurement group_id="O6" value="-5.00" spread="7.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 14 (n=8,9,9,9,7,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.50" spread="5.78"/>
                    <measurement group_id="O2" value="-5.78" spread="10.59"/>
                    <measurement group_id="O3" value="0.00" spread="5.15"/>
                    <measurement group_id="O4" value="-4.44" spread="4.93"/>
                    <measurement group_id="O5" value="-0.86" spread="4.38"/>
                    <measurement group_id="O6" value="-6.93" spread="9.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 16 (n=8,9,9,9,7,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.0" spread="5.10"/>
                    <measurement group_id="O2" value="-5.78" spread="7.61"/>
                    <measurement group_id="O3" value="-1.56" spread="5.70"/>
                    <measurement group_id="O4" value="-4.22" spread="4.12"/>
                    <measurement group_id="O5" value="1.00" spread="3.79"/>
                    <measurement group_id="O6" value="-3.36" spread="9.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Follow-up (n=9,9,9,9,7,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.89" spread="3.98"/>
                    <measurement group_id="O2" value="-5.22" spread="6.50"/>
                    <measurement group_id="O3" value="-3.22" spread="7.24"/>
                    <measurement group_id="O4" value="-4.44" spread="6.98"/>
                    <measurement group_id="O5" value="-2.29" spread="4.07"/>
                    <measurement group_id="O6" value="-3.50" spread="6.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Lactate Level at Day 6 and 14</title>
        <description>Baseline value was collected at 0 hour on Day 1 for lactate.</description>
        <time_frame>Baseline (Day 1), Day 6 and 14</time_frame>
        <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 PD parameter. Here 'n' signifies participants evaluable for this measure at specified time point for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received PF-04937319 10 milligram (mg) tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received PF-04937319 30 mg (3 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 50 mg</title>
            <description>Participants received PF-04937319 50 mg (5 tablets of 10 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 100 mg</title>
            <description>Participants received PF-04937319 100 mg tablet orally once daily for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 300 mg</title>
            <description>Participants received PF-04937319 300 mg (3 tablets of 100 mg) orally once daily for 14 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants received placebo matched to PF-04937319 tablet orally once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lactate Level at Day 6 and 14</title>
          <description>Baseline value was collected at 0 hour on Day 1 for lactate.</description>
          <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 PD parameter. Here 'n' signifies participants evaluable for this measure at specified time point for each arm group, respectively.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=9,9,9,9,9,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.64" spread="5.14"/>
                    <measurement group_id="O2" value="10.17" spread="3.07"/>
                    <measurement group_id="O3" value="14.14" spread="7.82"/>
                    <measurement group_id="O4" value="21.66" spread="9.45"/>
                    <measurement group_id="O5" value="11.57" spread="4.30"/>
                    <measurement group_id="O6" value="14.74" spread="8.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 6 (n=9,9,9,9,7,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.44" spread="7.95"/>
                    <measurement group_id="O2" value="1.02" spread="1.77"/>
                    <measurement group_id="O3" value="-2.08" spread="7.14"/>
                    <measurement group_id="O4" value="-6.08" spread="10.72"/>
                    <measurement group_id="O5" value="2.61" spread="6.60"/>
                    <measurement group_id="O6" value="-1.45" spread="9.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 14 (n=8,9,9,9,7,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="3.07"/>
                    <measurement group_id="O2" value="-0.09" spread="2.02"/>
                    <measurement group_id="O3" value="-3.88" spread="6.63"/>
                    <measurement group_id="O4" value="-6.97" spread="10.42"/>
                    <measurement group_id="O5" value="2.60" spread="2.98"/>
                    <measurement group_id="O6" value="-2.59" spread="8.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PF-04937319 10 mg</title>
          <description>Participants received PF-04937319 10 milligram (mg) tablet orally once daily for 14 days.</description>
        </group>
        <group group_id="E2">
          <title>PF-04937319 30 mg</title>
          <description>Participants received PF-04937319 30 mg (3 tablets of 10 mg) orally once daily for 14 days.</description>
        </group>
        <group group_id="E3">
          <title>PF-04937319 50 mg</title>
          <description>Participants received PF-04937319 50 mg (5 tablets of 10 mg) orally once daily for 14 days.</description>
        </group>
        <group group_id="E4">
          <title>PF-04937319 100 mg</title>
          <description>Participants received PF-04937319 100 mg tablet orally once daily for 14 days.</description>
        </group>
        <group group_id="E5">
          <title>PF-04937319 300 mg</title>
          <description>Participants received PF-04937319 300 mg (3 tablets of 100 mg) orally once daily for 14 days.</description>
        </group>
        <group group_id="E6">
          <title>Placebo</title>
          <description>Participants received placebo matched to PF-04937319 tablet orally once daily for 14 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Infected sebaceous cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

